

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hereditary sensory and autonomic neuropathies | D009477 | — | — | 1 | — | — | — | — | 1 |
| Drug common name | ELRAGLUSIB |
| INN | elraglusib |
| Description | Elraglusib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target glycogen synthase kinase-3 beta. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cc(C2=C(c3coc4ccc(F)cc34)C(=O)NC2=O)c2cc3c(cc21)OCO3 |
| PDB | — |
| CAS-ID | 1034895-42-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL483465 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | ND1SOF0DLU (ChemIDplus, GSRS) |
